Medtronic (NYSE:MDT) Updates FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2027 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 5.900-6.000 for the period, compared to the consensus earnings per share estimate of 6.060. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Piper Sandler lowered their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Daiwa Securities Group decreased their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Needham & Company LLC restated a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research note on Thursday, March 26th. Mizuho set a $100.00 target price on shares of Medtronic in a research report on Wednesday. Finally, Citigroup decreased their target price on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $105.45.

Medtronic Stock Performance

Shares of NYSE:MDT traded up $3.63 during trading on Wednesday, hitting $77.38. The stock had a trading volume of 8,487,375 shares, compared to its average volume of 9,027,719. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a 50-day simple moving average of $82.11 and a two-hundred day simple moving average of $92.49. Medtronic has a 12-month low of $73.31 and a 12-month high of $106.33. The stock has a market capitalization of $99.35 billion, a price-to-earnings ratio of 21.55, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.61 billion. During the same period last year, the business earned $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts expect that Medtronic will post 5.54 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s payout ratio is currently 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic topped quarterly expectations with revenue of $9.81 billion and adjusted EPS of $1.55, helped by broad-based strength in cardiovascular, diabetes, and medical-surgical businesses. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: Cardiac Ablation Solutions was a standout, with revenue up 78% globally and 124% in the U.S., signaling strong demand in a key growth area. Medtronic beats quarterly estimates on robust demand for heart devices
• Positive Sentiment: Management issued upbeat FY2027 guidance for 6.75% to 7.25% organic revenue growth and non-GAAP EPS of $5.90 to $6.00, while also raising the quarterly dividend to $0.72 per share. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: The company also highlighted strategic investments and product expansion in robotic surgery and cardiac ablation, which may support longer-term growth. Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera technologies broadens
• Neutral Sentiment: Shares were also supported by commentary that investors looked past margin pressure and tariff headwinds because the top-line beat and guidance outweighed those concerns. Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
• Negative Sentiment: Margin pressure remains a headwind, and some coverage noted that FY2027 guidance was not strong enough to fully eliminate investor concern about costs and tariffs. Medtronic (MDT) Stock Surges on Q4 Beat Despite Tariff Headwinds and Weak FY27 Outlook

Institutional Trading of Medtronic

Large investors have recently made changes to their positions in the company. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic during the fourth quarter worth approximately $29,000. Imprint Wealth LLC purchased a new stake in Medtronic during the 3rd quarter valued at about $31,000. Chapman Financial Group LLC purchased a new stake in Medtronic during the 2nd quarter valued at about $37,000. JPL Wealth Management LLC purchased a new stake in Medtronic during the 3rd quarter valued at about $40,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Medtronic by 96.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 223 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).